These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25073536)

  • 1. Colistin nephrotoxicity increases with age.
    Balkan II; Dogan M; Durdu B; Batirel A; Hakyemez IN; Cetin B; Karabay O; Gonen I; Ozkan AS; Uzun S; Demirkol ME; Akbas S; Kacmaz AB; Aras S; Mert A; Tabak F
    Scand J Infect Dis; 2014 Oct; 46(10):678-85. PubMed ID: 25073536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study.
    Dalfino L; Puntillo F; Ondok MJ; Mosca A; Monno R; Coppolecchia S; Spada ML; Bruno F; Brienza N
    Clin Infect Dis; 2015 Dec; 61(12):1771-7. PubMed ID: 26354965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between colistin dose and development of nephrotoxicity.
    Lee YJ; Wi YM; Kwon YJ; Kim SR; Chang SH; Cho S
    Crit Care Med; 2015 Jun; 43(6):1187-93. PubMed ID: 25756417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia.
    Omrani AS; Alfahad WA; Shoukri MM; Baadani AM; Aldalbahi S; Almitwazi AA; Albarrak AM
    Ann Clin Microbiol Antimicrob; 2015 Jan; 14():3. PubMed ID: 25591721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections.
    Durante-Mangoni E; Andini R; Signoriello S; Cavezza G; Murino P; Buono S; De Cristofaro M; Taglialatela C; Bassetti M; Malacarne P; Petrosillo N; Corcione A; Viscoli C; Utili R; Gallo C
    Clin Microbiol Infect; 2016 Dec; 22(12):984-989. PubMed ID: 27545697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study.
    Rocco M; Montini L; Alessandri E; Venditti M; Laderchi A; De Pascale G; Raponi G; Vitale M; Pietropaoli P; Antonelli M
    Crit Care; 2013 Aug; 17(4):R174. PubMed ID: 23945197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin.
    Ko Hj; Jeon Mh; Choo Ej; Lee Ej; Kim Th; Jun JB; Gil HW
    Nephron Clin Pract; 2011; 117(3):c284-8. PubMed ID: 20847571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colistin-induced Nephrotoxicity in a Tertiary Teaching Hospital.
    Al-Abdulkarim DA; Alzuwayed OA; Al Ammari M; Al Halwan S; Al Maklafi N; Thomas A
    Saudi J Kidney Dis Transpl; 2020; 31(5):1057-1061. PubMed ID: 33229769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria.
    Zaidi ST; Al Omran S; Al Aithan AS; Al Sultan M
    J Clin Pharm Ther; 2014 Jun; 39(3):272-6. PubMed ID: 24593154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system.
    Pogue JM; Lee J; Marchaim D; Yee V; Zhao JJ; Chopra T; Lephart P; Kaye KS
    Clin Infect Dis; 2011 Nov; 53(9):879-84. PubMed ID: 21900484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of acute kidney injury associated with intravenous colistin treatment.
    Kwon JA; Lee JE; Huh W; Peck KR; Kim YG; Kim DJ; Oh HY
    Int J Antimicrob Agents; 2010 May; 35(5):473-7. PubMed ID: 20089383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
    Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL
    Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients.
    Gauthier TP; Wolowich WR; Reddy A; Cano E; Abbo L; Smith LB
    Antimicrob Agents Chemother; 2012 May; 56(5):2392-6. PubMed ID: 22371891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium.
    Hassan MM; Gaifer Z; Al-Zakwani IS
    Int J Clin Pharm; 2018 Apr; 40(2):444-449. PubMed ID: 29542034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotoxicity associated with intravenous colistin in critically ill patients.
    Doshi NM; Mount KL; Murphy CV
    Pharmacotherapy; 2011 Dec; 31(12):1257-64. PubMed ID: 22122186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colistin nephrotoxicity in critically ill patients after implementation of a new dosing strategy.
    Ozel AS; Ergönül Ö; Korten V
    J Infect Dev Ctries; 2019 Oct; 13(10):877-885. PubMed ID: 32084017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
    Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
    Cheng CY; Sheng WH; Wang JT; Chen YC; Chang SC
    Int J Antimicrob Agents; 2010 Mar; 35(3):297-300. PubMed ID: 20045293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.
    Rigatto MH; Behle TF; Falci DR; Freitas T; Lopes NT; Nunes M; Costa LW; Zavascki AP
    J Antimicrob Chemother; 2015 May; 70(5):1552-7. PubMed ID: 25604744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.